Why MBX Biosciences, Inc.’s (MBX) Stock Is Down 6.76%
As of Thursday, October 08, MBX Biosciences, Inc.’s MBX share price has dipped by 6.76%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Commentary & Analysis
Why MBX Biosciences, Inc.’s (MBX) Stock Is Up 6.77%
As of Friday, October 02, MBX Biosciences, Inc.’s MBX share price has surged by 6.77%, which has investors questioning if this is right time to sell.Michael Rose
Why MBX Biosciences, Inc.’s (MBX) Stock Is Down 5.44%
As of Thursday, September 24, MBX Biosciences, Inc.’s MBX share price has dipped by 5.44%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why MBX Biosciences, Inc.’s (MBX) Stock Is Down 5.05%
As of Wednesday, September 23, MBX Biosciences, Inc.’s MBX share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why MBX Biosciences, Inc.’s (MBX) Stock Is Up 5.11%
As of Thursday, September 17, MBX Biosciences, Inc.’s MBX share price has surged by 5.11%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | MBX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,505.3 | $511.9 | 58% |
|
| Shares Out (Mil) | 47.7 | 42.8 | 46% |
|
| Institutional Ownership | 96.8% | 82.8% | 71% |
|
| Float (Mil) | 31.0 | 44.4 | 37% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 476 | 372 | 57% |
|
| Price Change (52-week) |
228.0% | 59.4% | 99% |
|
| Growth | MBX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | ($0.845) | ($3.054) | ($3.976) | |
| Month Ago EPS | ($0.845) | ($3.108) | ($3.955) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.738) | ($2.748) | ($3.929) | |
| Year/Year Chg | 8.6% | 28.2% | 95.4% | |
| Financials | MBX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($104) | ($11) | 11% |
|
| EPS (TTM) | ($2.405) | ($0.700) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($83) | ($7) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $5 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $6 | 21% |
|
| Enterprise Value (Q1) (Mil) | $2,779 | $494 | 53% |
|
| Valuation | MBX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.09 | 2.24 | 83% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MBX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (31.3%) | (22.2%) | 16% |
|
| ROE | (33.2%) | (21.4%) | 19% |
|
| Liabilities to Assets | 6.0% | 32.8% | 3% |
|
| F-Score | 2 | 3 | 7% |
|
MBX Biosciences, Inc. did not pass any screens on 10/12/2026.
